Inventor · disambiguated record
Mark Sliwkowski
Also filed as: SLIWKOWSKI MARK · SLIWKOWSKI MARK X
51 granted patents·56 pending applications·3,571 citations·filing 1997–2025
99Inventor score
Top patents by PatentIndex Score
107 records- 0199US7994135B2Monomethylvaline compounds capable of conjugation to ligandsSEATTLE GENETICS INC·Filed 2007·Granted Aug 9, 2011·164 cites·51 claims
- 0299US7964566B2Monomethylvaline compounds capable of conjugation to ligandsSEATTLE GENETICS INC·Filed 2007·Granted Jun 21, 2011·209 cites·60 claims
- 0399US7964567B2Monomethylvaline compounds capable of conjugation to ligandsSEATTLE GENETICS INC·Filed 2007·Granted Jun 21, 2011·134 cites·42 claims
- 0499US7862817B2Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodiesGENENTECH INC·Filed 2005·Granted Jan 4, 2011·126 cites·23 claims
- 0599US7745394B2Monomethylvaline compounds capable of conjugation to ligandsSEATTLE GENETICS INC·Filed 2007·Granted Jun 29, 2010·193 cites·44 claims
- 0699US7537931B2Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodiesGENENTECH INC·Filed 2006·Granted May 26, 2009·83 cites·24 claims
- 0799US7501122B2Treatment with anti-ErbB2 antibody combinationsGENENTECH INC·Filed 2005·Granted Mar 10, 2009·76 cites·9 claims
- 0899US7498030B2Treatment with anti-ErbB2 antibodies and anti-hormonal compoundsGENENTECH INC·Filed 2005·Granted Mar 3, 2009·69 cites·14 claims
- 0999US7485302B2Treatment with anti-ErbB2 antibodies and chemotherapeutic agentsGENENTECH INC·Filed 2006·Granted Feb 3, 2009·109 cites·30 claims
- 1099US6949245B1Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodiesGENENTECH INC·Filed 2000·Granted Sep 27, 2005·317 cites·24 claims
- 1198US8142784B2Antibody-drug conjugates and methodsEBENS JR ALLEN J·Filed 2008·Granted Mar 27, 2012·123 cites·6 claims
- 1298US7674589B2Methods for tissue analysisGENENTECH INC·Filed 2008·Granted Mar 9, 2010·80 cites·24 claims
- 1398US7618631B2Treatment with anti-ErbB2 antibodies and EGFR-targeted drugsGENENTECH INC·Filed 2005·Granted Nov 17, 2009·65 cites·28 claims
- 1498US7575748B1Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesGENENTECH INC·Filed 2006·Granted Aug 18, 2009·104 cites·27 claims
- 1598US7097840B2Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·266 cites·44 claims
- 1698US7041292B1Treating prostate cancer with anti-ErbB2 antibodiesGENENTECH INC·Filed 2000·Granted May 9, 2006·117 cites·14 claims
- 1798US6573043B1Tissue analysis and kits thereforGENENTECH INC·Filed 1998·Granted Jun 3, 2003·288 cites·15 claims
- 1897US7919254B2Tissue analysis and kits thereforGENENTECH INC·Filed 2010·Granted Apr 5, 2011·35 cites·7 claims
- 1997US7468252B2Methods for tissue analysisGENENTECH INC·Filed 2007·Granted Dec 23, 2008·51 cites·20 claims
- 2097US7344840B2Tissue analysis and kits thereforGENENTECH INC·Filed 2006·Granted Mar 18, 2008·43 cites·44 claims
- 2197US5968511AErbB3 antibodiesGENENTECH INC·Filed 1997·Granted Oct 19, 1999·287 cites·36 claims
- 2296US9518118B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2015·Granted Dec 13, 2016·22 cites·29 claims
- 2394US7704498B2ErbB4 antagonistsGENENTECH INC·Filed 2008·Granted Apr 27, 2010·18 cites·7 claims
- 2493US8652479B2Antibody-drug conjugates and methodsEBENS JR ALLEN J·Filed 2008·Granted Feb 18, 2014·25 cites·12 claims
- 2593US7285649B2Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodiesGENENTECH INC·Filed 2001·Granted Oct 23, 2007·45 cites·7 claims
- 2693US7129051B2Tissue analysis and kits thereforGENENTECH INC·Filed 2004·Granted Oct 31, 2006·36 cites·20 claims
- 2793US6905830B2Tissue analysis and kits thereforESOTERIX INC·Filed 2003·Granted Jun 14, 2005·51 cites·6 claims
- 2892US8163287B2Combination therapy of her expressing tumorsSLIWKOWSKI MARK X·Filed 2006·Granted Apr 24, 2012·47 cites·45 claims
- 2992US6096873AGamma-heregulinGENENTECH INC·Filed 1997·Granted Aug 1, 2000·81 cites·7 claims
- 3091US8663643B2Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of useBERRY LEANNE·Filed 2009·Granted Mar 4, 2014·47 cites·28 claims
- 3190US10179820B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2016·Granted Jan 15, 2019·6 cites·26 claims
- 3288US8597652B2Multispecific anti-HER antibodiesFUH GERMAINE·Filed 2010·Granted Dec 3, 2013·10 cites·14 claims
- 3388US7332579B2Antibodies to human ErbB4GENENTECH INC·Filed 2001·Granted Feb 19, 2008·18 cites·27 claims
- 3487US9327035B2Anti-HER antibodiesGENENTECH INC·Filed 2013·Granted May 3, 2016·8 cites·13 claims
- 3587US6696290B2ErbB2 and ErbB4 Chimeric Heteromultimeric AdhesinsGENENTECH INC·Filed 1999·Granted Feb 24, 2004·72 cites·9 claims
- 3686US7063961B2Heregulin variantsGENENTECH INC·Filed 2002·Granted Jun 20, 2006·24 cites·10 claims
- 3785US10639373B2Pyrrolobenzodiazepine antibody drug conjugates and methods of useGENENTECH INC·Filed 2018·Granted May 5, 2020·2 cites·48 claims
- 3883US10556966B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2018·Granted Feb 11, 2020·2 cites·44 claims
- 3982US12492263B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2022·Granted Dec 9, 2025·0 cites·15 claims
- 4082US6136558AHeregulin variantsGENENTECH INC·Filed 1998·Granted Oct 24, 2000·46 cites·32 claims
- 4181US7153828B2Use of heregulin as a growth factorUNIV IOWA RES FOUND·Filed 2003·Granted Dec 26, 2006·6 cites·11 claims
- 4281US6387638B1Heregulin variantsGENENTECH INC·Filed 1998·Granted May 14, 2002·51 cites·24 claims
- 4381US2023201210A1Combinations of anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 4480US10058613B2Pyrrolobenzodiazepine antibody drug conjugates and methods of useGENENTECH INC·Filed 2016·Granted Aug 28, 2018·2 cites·10 claims
- 4579US10314846B2Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepinesGENENTECH INC·Filed 2017·Granted Jun 11, 2019·2 cites·64 claims
- 4675US6916624B2Antibodies that bind gamma-heregulinGENENTECH INC·Filed 2002·Granted Jul 12, 2005·5 cites·4 claims
- 4775US2020255539A1Anti-HER2 Antibodies and ImmunoconjugatesGENENTECH INC·Filed 2019·Application pending·0 cites
- 4874US2025161315A1Combinations of anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2025·Application pending·0 cites
- 4970US2014212411A1Methods of treatment using anti-erbb antibody-maytansinoid conjugatesSCHWALL GAIL COLBERN·Filed 2013·Application pending·0 cites
- 5069US7659368B2ErbB2 and ErbB3 chimeric heteromultimer adhesinsGENENTECH INC·Filed 2003·Granted Feb 9, 2010·4 cites·12 claims
Showing the top 50 of 107 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark Sliwkowski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →